Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | Q9HBH1 | 2/20 | 0.32 | |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4440645 | 0.83 | TSHR (0.46) | USP2TSHRALDH1A1PDFCA2 | |
| SCHEMBL21253928 | 0.82 | TSHR (0.43) | USP2TSHRALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL19759002 | 0.82 | ALDH1A1 (0.39) | USP2TSHRALDH1A1PDFCA2 | |
| SCHEMBL28042046 | 0.79 | PDF (0.48) | ALDH1A1CHRNB2CHRNB4CHRNA4PDF | |
| SCHEMBL6339894 | 0.77 | CA1 (0.50) | USP2TSHRALDH1A1CA2MAPK1 | |
| SCHEMBL6339895 | 0.77 | CA1 (0.50) | USP2TSHRALDH1A1CA2MAPK1 | |
| SCHEMBL6115797 | 0.74 | CHRM1 (0.48) | USP2TSHRALDH1A1PDFCA2 | |
| SCHEMBL2874645 | 0.74 | USP2 (0.39) | USP2TSHRALDH1A1CA2MAPK1 | |
| SCHEMBL15314155 | 0.74 | CHRM1 (0.48) | USP2TSHRALDH1A1PDFCA2 | |
| SCHEMBL20045056 | 0.73 | ALDH1A1 (0.42) | USP2TSHRALDH1A1CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580712-B2 | Bis(dialkylamide) compounds and diverse applications thereof | RHODIA OPERATIONS (FR) | 2013-11-12 | — | — | US | disclosed |
| US-20100113279-A1 | NOVEL BIS(DIALKYLAMIDE) COMPOUNDS AND DIVERSE APPLICATIONS THEREOF | SPECIALTY OPERATIONS FRANCE (FR) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113279-A1 | NOVEL BIS(DIALKYLAMIDE) COMPOUNDS AND DIVERSE APPLICATIONS THEREOF | C1R, CBR3, CWC15 | USP2 3539/4885TSHR 1446/4885ALDH1A1 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.